Disodium cromoglycate suppresses the induction of cysteinyl leukotriene synthesis during granulocytic differentiation in HL-60 cells

Zaitsu, Masafumi; Honjo, Kinji; Ishii, Eiichi; Hamasaki, Yuhei

doi:10.1016/j.rmed.2003.09.016

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCG participates in various inhibitory effects among the process, such as airway inflammation, release of chemical mediators from mast cells, 17 IgE production, 18 T-cell and eosinophil accumulation, 19 eosinophil activation, 20,21 allergic inflammation, 22,23 inflammatory cytokine production, 22 activation of afferent sensory nerves (C-fibers), 24 and induction of cysteinyl leukotoriene synthesis. 25 Combination therapy using SCG may be effective in controlling severe refractory asthmatic symptoms. One report mentioned that adding of nebulized SCG (alone or with b 2 agonist inhaled by nebulizer) in patients with severe asthma had improved pulmonary functions and decreased requirement of oral corticosteroids.…”

mentioning

confidence: 99%

Effects of nebulized sodium cromoglycate on adult patients with severe refractory asthma

Sugiyama

Adachi

Kiuchi

et al. 2006

Respiratory Medicine

View full text Add to dashboard Cite

Many patients with severe refractory asthma, which is insufficiently controlled by additional high-dose of inhaled corticosteroids, require oral corticosteroids and/or immunosuppressant. Clinicians should seek for suitable medications, for its' chronic use may induce high risk of side effects.The purpose of this study was to evaluate the efficacy and safety of nebulized sodium cromoglycate (3-4 times/day) in adult severe asthmatic patients with poorly controlled asthmatic symptoms, despite treatments with high-dose inhaled corticosteroids.Adult patients with severe asthma (n ¼ 251) were enrolled in a randomized clinical trial at 30 medical centers in Japan. Isotonic saline was used as placebo. The study was conducted for 10 weeks; with initial 2 weeks of observation followed by 8 weeks of treatments. Efficacy was primarily evaluated based on improvements in morning peak expiratory flow after treatment.All patients who applied inhalation of nebulized sodium cromoglycate (SCG group) or saline (Controls) were treated with high-dose of inhaled corticosteroids (median of beclomethasone dipropionate equivalent dose: 1600 mg/day s) and second-line control therapy including oral corticosteroids. There was no significant difference in morning peak expiratory flow between SCG group and controls. However, when patients were stratified into atopic and non-atopic groups, morning peak expiratory flow had significantly improved in the atopic SCG group compared to atopic Controls.Additional inhalation of nebulized sodium cromoglycate with inhaled corticosteroids is effective even in patients with severe atopic asthma. This finding shows that nebulized sodium cromoglycate is expected to be new second-line therapeutic option in severe asthma.

show abstract